Table 1 Baseline characteristics of patients with severe COVID-19 and HBV co-infection
Characteristics | All patients N = 105 | Survivors N = 87 | Non-survivors N = 18 | P value |
|---|---|---|---|---|
Median age (IQR), year | 62 (54,71) | 62 (53, 70) | 70 (58,75) | 0.024 |
Gender, n (%) | ||||
 Female | 45 (42.9) | 39 (44.8) | 6 (33.3) | 0.370 |
 Male | 60 (57.1) | 48 (55.2) | 12 (66.7) |  |
Comorbidity | ||||
 Diabetes, n (%) | 16 (15.2) | 12 (13.8) | 4 (22.2) | 0.585 |
 Hypertension, n (%) | 38 (36.2) | 29 (33.3) | 9 (50.0) | 0.180 |
 Coronary heart disease, n (%) | 11 (10.5) | 8 (9.2) | 3 (16.7) | 0.603 |
 COPD, n (%) | 5 (4.8) | 2 (2.3) | 3 (16.7) | 0.034 |
 Cancer, n (%) | 9 (8.6) | 6 (6.9) | 3 (16.7) | 0.376 |
 Cirrhosis, n (%) | 15 (14.3) | 11 (12.6) | 4 (22.2) | 0.492 |
HBV infection, n (%) | ||||
 HBeAg positive, n (%) | 5 (4.8) | 3 (3.4) | 2 (11.1) | 0.206 |
 HBeAb positive, n (%) | 18 (17.1) | 16 (18.4) | 2 (11.1) | 0.659 |
 HBcAb positive, n (%) | 105 (100) | 87 (100) | 18 (100) | > 0.999 |
Anti-HBV treatment history, n (%) | 8 (7.6) | 5 (5.7) | 3 (16.7) | 0.271 |
Time from symptom onset to admission, median (IQR), days | 14 (8, 20) | 14 (8, 21) | 10 (7, 16) | 0.247 |
Drugs treatment during hospitalization | ||||
 Corticosteroid treatment, n (%) | 55 (52.4) | 39 (44.8) | 16 (88.9) | 0.001 |
 IFN-α, n (%) | 16 (15.2) | 13 (14.9) | 3 (16.7) | 0.853 |
 Thymosin treatment, n (%) | 29 (27.6) | 22 (25.3) | 7 (38.9) | 0.240 |
 Anti-HBV treatment, n (%) | 9 (8.6) | 8 (9.2) | 1 (5.6) | 0.968 |
 Gamma globulin treatment, n (%) | 36 (34.3) | 25 (28.7) | 11 (61.1) | 0.008 |
 Anticoagulant therapy, n (%) | 21 (20.0) | 14 (16.1) | 7 (38.9) | 0.028 |